Numerof & Associates January 24, 2025

The challenges in bringing new products to market successfully have never been greater. In the past product approval meant demonstrating safety and efficacy to regulatory bodies in discrete countries—with a placebo comparator. Patients included in randomized clinical trials were subjected to inclusion and exclusion criteria based on disease parameters—not diversity in age, race, gender or other factors.

While...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article